ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1293

Factors Associated with Early Hospital Readmission in Systemic Lupus Erythematosus: Data from National Readmission Database

Rashmi Dhital1, Joshua Baker2, Paras Karmacharya3, Anthony Donato4 and Dilli Poudel2, 1Reading Hospital and Medical Center, West Reading, 2University of Pennsylvania, Philadelphia, PA, 3Mayo Clinic, Rochester MN, ROCHESTER, MN, 4Reading Hospital and Medical Center, West Reading, PA

Meeting: ACR Convergence 2020

Keywords: Epidemiology, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Early hospital readmission is a major healthcare burden. Studies evaluating factors associated with readmissions in rheumatic diseases are sparse. Our aim was to use a large national database to identify rates and the predictors of readmission in SLE as compared to common medical conditions with known high readmission rates including congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD).

Methods: We used the US nationwide readmission database (NRD, 2010-2014) to identify index adult (≥ 18 years) discharges with SLE, CHF, and COPD using ICD-9 codes in the first 5 diagnosis positions, and assessed their rates of readmission (defined as “early” readmission within 30 days). Index discharges with same-day transfers or those discharged as deceased were excluded. Discharges with the same diagnosis after 30 days from the previous index discharge date could count as another index, thus, allowing one patient to contribute to multiple observations. We performed multivariate regression to identify factors independently associated with early readmission, including demographic, hospital, and clinical factors. Comorbidities that were significant in univariate analysis (p≤0.05) were included in the multivariate model. We accounted for the clustering of multiple index discharges within the same patient using generalized estimating equations.

Results: In the combined data from 2010-2014, we identified 351,219 index SLE discharges, and compared them to 3,022,240 CHF, and 4,052,574 COPD index discharges. The readmission rate was 16.9% for SLE compared to 21.3% for CHF and 18.4% for COPD. Readmission was higher in males (19.5 %, 21.4 % and 19.4%) compared to females (16.6%, 21.2% and 17.7 %) for SLE, CHF and COPD, respectively.

Some demographic and hospital factors associated with higher odds of readmission in SLE included non-private insurance, longer length-of-stay at index hospitalization, and lowest income quartile. Age >65 and female sex were associated with reduced odds of readmission. Discharges against medical advice (AMA) had a higher odds of readmission in all cohorts (Table 1).

Among select diagnoses present in the index SLE discharges, the top 5 comorbid conditions associated with highest odds of readmission were chronic kidney disease (OR: 1.31, 95% CI: 1.23 – 1.39, p< 0.001), alcoholic liver disease (OR: 1.30 , 95% CI: 1.02 -1.65, p=0.03), anemia (OR 1.24, 95% CI: 1.20 – 1.28, p< 0.001) , coagulation disorders (OR: 1.19, 95% CI 1.14 – 1.25, p< 0.001), and CHF (OR: 1.17, 95% CI: 1.11– 1.23, p< 0.001). Acute kidney injury was associated with early readmission in CHF and SLE. Carditis (peri-, myo- and endocarditis) and cardiomyopathy were associated with increased readmission only in SLE (Fig 1).

Conclusion: We found readmission in SLE to be comparable to that in CHF and COPD. Higher readmission in younger SLE patients likely reflects the more severe phenotype in this group. Similarly, the presence of anemia, coagulopathy, and myopericarditis conferred higher readmission risk, likely reflecting more severe SLE with organ involvement. Studying the role of various common and unique predictors in a prospective setting could identify avenues for improving inpatient and transitional care in SLE.

Table 1: Multivariate analysis of demographic, hospital and clinical factors associated with early readmission in systemic lupus erythematosus (SLE), congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD)

Figure 1: Multivariate analysis of comorbidities present at index discharges associated with early readmission in systemic lupus erythematosus (SLE), congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD)


Disclosure: R. Dhital, None; J. Baker, None; P. Karmacharya, National Center for Advancing Translational Science, 2, SPARTAN (Spondyloarthritis Research and Treatment Network), 2; A. Donato, None; D. Poudel, None.

To cite this abstract in AMA style:

Dhital R, Baker J, Karmacharya P, Donato A, Poudel D. Factors Associated with Early Hospital Readmission in Systemic Lupus Erythematosus: Data from National Readmission Database [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/factors-associated-with-early-hospital-readmission-in-systemic-lupus-erythematosus-data-from-national-readmission-database/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-early-hospital-readmission-in-systemic-lupus-erythematosus-data-from-national-readmission-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology